The 34th Congress of the European Committe for Treatment and Research in Multiple Sclerosis program catches the most exciting new developments in all areas of multiple sclerosis, including treatment, genetics, pathology, imaging, immunology and epidemiology.
Because of the growing number and complexity of treatment options, the dialogue between “stakeholders” (neurologists, patients, health insurers, pharmaceutical industry) on the one side, and regulatory authorities on the other, is more important than ever.
Body Interact scenarios featuring out-patients with multiple sclerosis, captured the attention of the attendees and promoted interesting clinical discussions.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
